Radiation Toxicity Treatment Market
授權報價
| Single User License | $4,500 USD |
| Multiple User License | $5,500 USD |
| Custom Research License | $8,000 USD |
完整報告名稱與涵蓋範圍
Radiation Toxicity Treatment Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Product (Colony Stimulating Factors, Potassium Iodide, Prussian Blue Diethylenetriamine Pentaacetic Acid, Others), By Indication (Acute Radiation Syndrome, Chronic Radiation Syndrome), By Radiation Type (Ionizing Radiation, Non-ionizing Radiation), By End-user (Hospitals & Clinics, Ambulatory Care Centers, Others) By Region & Competition, 2021-2031F
報告摘要
Market Overview
The Global Radiation Toxicity Treatment Market, encompassing pharmaceuticals and biological agents aimed at mitigating damage to healthy tissues from ionizing radiation, predominantly from cancer radiotherapy, is projected to grow from USD 2.52 Billion in 2025 to USD 3.47 Billion by 2031, achieving a 5.48% CAGR. A primary driver for this growth is the escalating global cancer burden, which necessitates frequent radiation therapy and expands the patient pool requiring toxicity management, fostering consistent demand for protective interventions as healthcare providers prioritize patient quality of life; the American Cancer Society's projection of 2,041,910 new cancer cases in the U.S. in 2025 underscores this. However, stringent regulatory requirements for approving radioprotective drugs significantly impede market expansion, as the development of these agents mandates complex clinical trials to ensure they do not reduce cancer treatment efficacy, leading to prolonged timelines and substantial financial investment that restricts rapid commercialization and limits new market entrants.
Market Driver
The escalating global incidence of cancer and the concurrent rise in radiation therapy adoption are the primary drivers for the radiation toxicity treatment market. Increased patient volumes lead to a surge in radiotherapy procedures, necessitating effective interventions to manage collateral tissue damage and enhance patient quality of life, compelling healthcare systems to mitigate side effects like mucositis and dermatitis, thereby fueling demand for radioprotective pharmaceuticals. The World Health Organization's February 2024 projection of over 35 million new cancer cases by 2050—a 77% increase from 2022 levels—highlights this rapidly expanding patient pool. Furthermore, strategic government stockpiling for nuclear and radiological defense, driven by heightened geopolitical tensions and national security preparedness, accelerates market growth through active investment in medical countermeasures for acute radiation syndrome (ARS); examples include HOPO Therapeutics' $226 million contract in October 2024 for oral treatments for radioactive heavy metal exposure and Amgen's reported $128 million in U.S. government orders for Nplate in 2024.
Market Challenge
The stringent regulatory landscape governing the approval of radioprotective drugs significantly impedes the expansion of the radiation toxicity treatment market. Regulatory bodies enforce rigorous safety standards, demanding extensive and complex clinical trials to guarantee these agents do not interfere with the therapeutic efficacy of radiation in cancer treatment. This necessitates demonstrating that products protect healthy tissue without inadvertently shielding tumor cells, a technical hurdle that extends approval processes and delays the commercial availability of potential therapies. These protracted timelines impose substantial financial burdens on pharmaceutical developers, creating a formidable barrier to entry, particularly for smaller biotechnology firms lacking the capital to sustain long-term trials. The biopharmaceutical industry's investment of nearly $103 billion in research and development in 2024, as reported by PhRMA, illustrates this immense financial pressure, which restricts the number of new entrants and reduces the overall volume of innovative treatments reaching the market.
Market Trends
A significant trend reshaping the market is the rising interest in plant-derived and natural radioprotective agents, driven by the demand for safer, low-toxicity alternatives to traditional synthetic compounds. Developers are increasingly investigating bioactive compounds like genistein, which offer ease of administration and favorable safety profiles suitable for prophylactic use in both clinical and biodefense settings, thereby accelerating the transition of natural products from academic research to industrial-scale manufacturing; Humanetics Corporation, for instance, initiated a manufacturing collaboration in March 2025, supported by a $5.1 million Department of Defense grant, to advance BIO 300, a soy-derived agent for preventing acute radiation syndrome. Concurrently, there is a distinct shift towards post-exposure radiomitigator research, prioritizing therapeutics that can limit tissue damage when administered after radiation exposure, addressing a critical gap for unanticipated nuclear incidents and managing oncology patient side effects where pre-treatment is not feasible. Companies are actively securing substantial capital to advance clinical pipelines focused on these mitigation strategies, specifically targeting inflammatory pathways to reverse radiation-induced injury, as evidenced by Soligenix Inc.'s September 2025 public offering which raised $7.5 million to support its biotherapeutic pipeline for conditions like oral mucositis and acute radiation syndrome.
Key Market Players
* Amgen Inc.
* Jubilant Pharma Limited
* Tanner Pharma Group
* Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG
* Recipharm AB
* Mission Pharmacal Company
* Partner Therapeutics, Inc.
* Novartis AG
* Viatris Inc.
* Coherus Biosciences Inc
Report Scope
In this report, the Global Radiation Toxicity Treatment Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:
# Radiation Toxicity Treatment Market, By Product
* Colony Stimulating Factors
* Potassium Iodide
* Prussian Blue Diethylenetriamine Pentaacetic Acid
* Others
# Radiation Toxicity Treatment Market, By Indication
* Acute Radiation Syndrome
* Chronic Radiation Syndrome
# Radiation Toxicity Treatment Market, By Radiation Type
* Ionizing Radiation
* Non-ionizing Radiation
# Radiation Toxicity Treatment Market, By End-user
* Hospitals & Clinics
* Ambulatory Care Centers
* Others
# Radiation Toxicity Treatment Market, By Region
* North America
United States
Canada
Mexico
* Europe
France
United Kingdom
Italy
Germany
Spain
* Asia Pacific
China
India
Japan
Australia
South Korea
* South America
Brazil
Argentina
Colombia
* Middle East & Africa
South Africa
Saudi Arabia
UAE
Competitive Landscape
Company Profiles: Detailed analysis of the major companies present in the Global Radiation Toxicity Treatment Market.
Available Customizations:
Global Radiation Toxicity Treatment Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:
Company Information
* Detailed analysis and profiling of additional market players (up to five).
目錄 Table of Contents
1. Product Overview
1.1. Market Definition
1.2. Scope of the Market
1.2.1. Markets Covered
1.2.2. Years Considered for Study
1.2.3. Key Market Segmentations
2. Research Methodology
2.1. Objective of the Study
2.2. Baseline Methodology
2.3. Key Industry Partners
2.4. Major Association and Secondary Sources
2.5. Forecasting Methodology
2.6. Data Triangulation & Validation
2.7. Assumptions and Limitations
3. Executive Summary
3.1. Overview of the Market
3.2. Overview of Key Market Segmentations
3.3. Overview of Key Market Players
3.4. Overview of Key Regions/Countries
3.5. Overview of Market Drivers, Challenges, Trends
4. Voice of Customer
5. Global Radiation Toxicity Treatment Market Outlook
5.1. Market Size & Forecast
5.1.1. By Value
5.2. Market Share & Forecast
5.2.1. By Product (Colony Stimulating Factors, Potassium Iodide, Prussian Blue Diethylenetriamine Pentaacetic Acid, Others)
5.2.2. By Indication (Acute Radiation Syndrome, Chronic Radiation Syndrome)
5.2.3. By Radiation Type (Ionizing Radiation, Non-ionizing Radiation)
5.2.4. By End-user (Hospitals & Clinics, Ambulatory Care Centers, Others)
5.2.5. By Region
5.2.6. By Company (2025)
5.3. Market Map
6. North America Radiation Toxicity Treatment Market Outlook
6.1. Market Size & Forecast
6.1.1. By Value
6.2. Market Share & Forecast
6.2.1. By Product
6.2.2. By Indication
6.2.3. By Radiation Type
6.2.4. By End-user
6.2.5. By Country
6.3. North America: Country Analysis
6.3.1. United States Radiation Toxicity Treatment Market Outlook
6.3.1.1. Market Size & Forecast
6.3.1.1.1. By Value
6.3.1.2. Market Share & Forecast
6.3.1.2.1. By Product
6.3.1.2.2. By Indication
6.3.1.2.3. By Radiation Type
6.3.1.2.4. By End-user
6.3.2. Canada Radiation Toxicity Treatment Market Outlook
6.3.2.1. Market Size & Forecast
6.3.2.1.1. By Value
6.3.2.2. Market Share & Forecast
6.3.2.2.1. By Product
6.3.2.2.2. By Indication
6.3.2.2.3. By Radiation Type
6.3.2.2.4. By End-user
6.3.3. Mexico Radiation Toxicity Treatment Market Outlook
6.3.3.1. Market Size & Forecast
6.3.3.1.1. By Value
6.3.3.2. Market Share & Forecast
6.3.3.2.1. By Product
6.3.3.2.2. By Indication
6.3.3.2.3. By Radiation Type
6.3.3.2.4. By End-user
7. Europe Radiation Toxicity Treatment Market Outlook
7.1. Market Size & Forecast
7.1.1. By Value
7.2. Market Share & Forecast
7.2.1. By Product
7.2.2. By Indication
7.2.3. By Radiation Type
7.2.4. By End-user
7.2.5. By Country
7.3. Europe: Country Analysis
7.3.1. Germany Radiation Toxicity Treatment Market Outlook
7.3.1.1. Market Size & Forecast
7.3.1.1.1. By Value
7.3.1.2. Market Share & Forecast
7.3.1.2.1. By Product
7.3.1.2.2. By Indication
7.3.1.2.3. By Radiation Type
7.3.1.2.4. By End-user
7.3.2. France Radiation Toxicity Treatment Market Outlook
7.3.2.1. Market Size & Forecast
7.3.2.1.1. By Value
7.3.2.2. Market Share & Forecast
7.3.2.2.1. By Product
7.3.2.2.2. By Indication
7.3.2.2.3. By Radiation Type
7.3.2.2.4. By End-user
7.3.3. United Kingdom Radiation Toxicity Treatment Market Outlook
7.3.3.1. Market Size & Forecast
7.3.3.1.1. By Value
7.3.3.2. Market Share & Forecast
7.3.3.2.1. By Product
7.3.3.2.2. By Indication
7.3.3.2.3. By Radiation Type
7.3.3.2.4. By End-user
7.3.4. Italy Radiation Toxicity Treatment Market Outlook
7.3.4.1. Market Size & Forecast
7.3.4.1.1. By Value
7.3.4.2. Market Share & Forecast
7.3.4.2.1. By Product
7.3.4.2.2. By Indication
7.3.4.2.3. By Radiation Type
7.3.4.2.4. By End-user
7.3.5. Spain Radiation Toxicity Treatment Market Outlook
7.3.5.1. Market Size & Forecast
7.3.5.1.1. By Value
7.3.5.2. Market Share & Forecast
7.3.5.2.1. By Product
7.3.5.2.2. By Indication
7.3.5.2.3. By Radiation Type
7.3.5.2.4. By End-user
8. Asia Pacific Radiation Toxicity Treatment Market Outlook
8.1. Market Size & Forecast
8.1.1. By Value
8.2. Market Share & Forecast
8.2.1. By Product
8.2.2. By Indication
8.2.3. By Radiation Type
8.2.4. By End-user
8.2.5. By Country
8.3. Asia Pacific: Country Analysis
8.3.1. China Radiation Toxicity Treatment Market Outlook
8.3.1.1. Market Size & Forecast
8.3.1.1.1. By Value
8.3.1.2. Market Share & Forecast
8.3.1.2.1. By Product
8.3.1.2.2. By Indication
8.3.1.2.3. By Radiation Type
8.3.1.2.4. By End-user
8.3.2. India Radiation Toxicity Treatment Market Outlook
8.3.2.1. Market Size & Forecast
8.3.2.1.1. By Value
8.3.2.2. Market Share & Forecast
8.3.2.2.1. By Product
8.3.2.2.2. By Indication
8.3.2.2.3. By Radiation Type
8.3.2.2.4. By End-user
8.3.3. Japan Radiation Toxicity Treatment Market Outlook
8.3.3.1. Market Size & Forecast
8.3.3.1.1. By Value
8.3.3.2. Market Share & Forecast
8.3.3.2.1. By Product
8.3.3.2.2. By Indication
8.3.3.2.3. By Radiation Type
8.3.3.2.4. By End-user
8.3.4. South Korea Radiation Toxicity Treatment Market Outlook
8.3.4.1. Market Size & Forecast
8.3.4.1.1. By Value
8.3.4.2. Market Share & Forecast
8.3.4.2.1. By Product
8.3.4.2.2. By Indication
8.3.4.2.3. By Radiation Type
8.3.4.2.4. By End-user
8.3.5. Australia Radiation Toxicity Treatment Market Outlook
8.3.5.1. Market Size & Forecast
8.3.5.1.1. By Value
8.3.5.2. Market Share & Forecast
8.3.5.2.1. By Product
8.3.5.2.2. By Indication
8.3.5.2.3. By Radiation Type
8.3.5.2.4. By End-user
9. Middle East & Africa Radiation Toxicity Treatment Market Outlook
9.1. Market Size & Forecast
9.1.1. By Value
9.2. Market Share & Forecast
9.2.1. By Product
9.2.2. By Indication
9.2.3. By Radiation Type
9.2.4. By End-user
9.2.5. By Country
9.3. Middle East & Africa: Country Analysis
9.3.1. Saudi Arabia Radiation Toxicity Treatment Market Outlook
9.3.1.1. Market Size & Forecast
9.3.1.1.1. By Value
9.3.1.2. Market Share & Forecast
9.3.1.2.1. By Product
9.3.1.2.2. By Indication
9.3.1.2.3. By Radiation Type
9.3.1.2.4. By End-user
9.3.2. UAE Radiation Toxicity Treatment Market Outlook
9.3.2.1. Market Size & Forecast
9.3.2.1.1. By Value
9.3.2.2. Market Share & Forecast
9.3.2.2.1. By Product
9.3.2.2.2. By Indication
9.3.2.2.3. By Radiation Type
9.3.2.2.4. By End-user
9.3.3. South Africa Radiation Toxicity Treatment Market Outlook
9.3.3.1. Market Size & Forecast
9.3.3.1.1. By Value
9.3.3.2. Market Share & Forecast
9.3.3.2.1. By Product
9.3.3.2.2. By Indication
9.3.3.2.3. By Radiation Type
9.3.3.2.4. By End-user
10. South America Radiation Toxicity Treatment Market Outlook
10.1. Market Size & Forecast
10.1.1. By Value
10.2. Market Share & Forecast
10.2.1. By Product
10.2.2. By Indication
10.2.3. By Radiation Type
10.2.4. By End-user
10.2.5. By Country
10.3. South America: Country Analysis
10.3.1. Brazil Radiation Toxicity Treatment Market Outlook
10.3.1.1. Market Size & Forecast
10.3.1.1.1. By Value
10.3.1.2. Market Share & Forecast
10.3.1.2.1. By Product
10.3.1.2.2. By Indication
10.3.1.2.3. By Radiation Type
10.3.1.2.4. By End-user
10.3.2. Colombia Radiation Toxicity Treatment Market Outlook
10.3.2.1. Market Size & Forecast
10.3.2.1.1. By Value
10.3.2.2. Market Share & Forecast
10.3.2.2.1. By Product
10.3.2.2.2. By Indication
10.3.2.2.3. By Radiation Type
10.3.2.2.4. By End-user
10.3.3. Argentina Radiation Toxicity Treatment Market Outlook
10.3.3.1. Market Size & Forecast
10.3.3.1.1. By Value
10.3.3.2. Market Share & Forecast
10.3.3.2.1. By Product
10.3.3.2.2. By Indication
10.3.3.2.3. By Radiation Type
10.3.3.2.4. By End-user
11. Market Dynamics
11.1. Drivers
11.2. Challenges
12. Market Trends & Developments
12.1. Merger & Acquisition (If Any)
12.2. Product Launches (If Any)
12.3. Recent Developments
13. Global Radiation Toxicity Treatment Market: SWOT Analysis
14. Porter's Five Forces Analysis
14.1. Competition in the Industry
14.2. Potential of New Entrants
14.3. Power of Suppliers
14.4. Power of Customers
14.5. Threat of Substitute Products
15. Competitive Landscape
15.1. Amgen Inc.
15.1.1. Business Overview
15.1.2. Products & Services
15.1.3. Recent Developments
15.1.4. Key Personnel
15.1.5. SWOT Analysis
15.2. Jubilant Pharma Limited
15.3. Tanner Pharma Group
15.4. Heyl Chemisch-pharmazeutische Fabrik GmbH & Co. KG
15.5. Recipharm AB
15.6. Mission Pharmacal Company
15.7. Partner Therapeutics, Inc.
15.8. Novartis AG
15.9. Viatris Inc.
15.10. Coherus Biosciences Inc
16. Strategic Recommendations
17. About Us & Disclaimer
提及公司
同分類最新報告（醫療與生命科學）
常見問題
這份報告可以先索取樣本嗎？
可以。建議購買前先申請樣本，提出申請後約 2 個工作天內提供，您可以先確認內容涵蓋範圍是否符合需求。
報告價格如何計算？
報告以美元標價，台幣報價依當日匯率換算並加計 5% 營業稅。不同授權版本（單人／多人／企業全站）價格不同，量子訊息會評估您的使用情境後提供最優惠報價。
下單後多久交付？如何付款？
一般 3–7 個工作天交付，實際依出版商狀況於下單前確認。收到報告確認無誤後開立台幣發票，30 天內電匯付款即可。
量子訊息有限公司為 TechSci Research 在台灣的授權代理，提供報告購買、樣本申請與授權諮詢。電話 +886 2 7751 5192 ・ 聯絡我們